Abstract
Background
Karbalex, with its carbamazepine as an active ingredient, is used to treat various types of epilepsy. Despite being uncommon, the present case highlights how crucial it is to take oral lichenoid reactions into account, particularly in patients who use Karbalex, when making a differential diagnosis of oral mucosal lesions.
Case Presentation
The rare case of a 20-year-old man with a history of generalised epilepsy is described in this article. He sought consultation because of pain from mouth sores and a burning sensation when consuming cold, hot, and spicy meals, among other symptoms. For the previous five months, the patient was taking Karbalex Retard 600 mg. The diagnosis of bilateral symmetrical oral lichenoid reaction caused by Karbalex Retard 600 mg was confirmed by clinical and histological analysis. The patient was treated by stopping Karbalex Retard 600 mg and beginning with Tegretol 400 mg. The patient noticed that his mouth was starting to recover 2 months after stopping Karbalex Retard. After an additional month, all the symptoms of oral lichenoid reactions disappeared totally, which confirmed the diagnosis.
Conclusion
This is an unusual case of a bilateral symmetrical oral lichenoid reaction caused by Karbalex Retard (Carbamazepine) 600 in an epileptic patient. Despite being uncommon, this case report is worth highlighting because, by removing the differential diagnosis and offering an early diagnosis, it may prevent vulnerable individuals from displaying severe symptoms.
Similar content being viewed by others
Data Availability
No datasets were generated or analysed during the current study.
Code Availability
Not applicable.
References
Liba Laboratories Inc., Beykoz/Istanbul Production place: Nobel İlaç San. and Tic. Inc. Sancaklar/Düzce . Instruction manual. Approved on 13/12/2019. Available at: https://www.liba.com.tr/urunler/karbalex-600-mg-uzatilmis-salimli-tablet/https://www.liba.com.tr/pdf/karbalex600-kt.pdf.
Chen Z, Brodie MJ, Ding D, Kwan P. Editorial: Epidemiology of epilepsy and seizures. Front Epidemiol. 2023;3:1273163. https://doi.org/10.3389/fepid.2023.1273163.
Teoh L, Moses G, McCullough MJ. A review and guide to drug-associated oral adverse effects-oral mucosal and lichenoid reactions. Part 2. J Oral Pathol Med. 2019;48(7):637–46. https://doi.org/10.1111/jop.12910.
Tesic-Rajkovic S, Radovanovic-Dinic B. Lesions in the oral cavity and esophagus caused by prescribed drugs: a review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022;166(1):21–7. https://doi.org/10.5507/bp.2021.059.
Binnie R, Dobson ML, Chrystal A, Hijazi K. Oral lichen planus and lichenoid lesions - challenges and pitfalls for the general dental practitioner. Br Dent J. 2024;236(4):285–92. https://doi.org/10.1038/s41415-024-7063-y.
Alajbeg I, Challacombe SJ, Holmstrup P, Jontell M. Red and white lesions of the oral mucosa. Burket’s Oral Medicine. 2021Aug;30:85–138. https://doi.org/10.1002/9781119597797.ch4.
Schlosser BJ. Lichen planus and lichenoid reactions of the oral mucosa. Dermatol Ther. 2010;23(3):251–67. https://doi.org/10.1111/j.1529-8019.2010.01322.x.
Suzuki T, Suemitsu M, Nakayama M, Taguchi C, Ukigaya M, Nakamura C, et al. Histopathological and immunohistochemical study of the distinction between oral lichen planus and oral lichenoid lesions. Open J Stomatol. 2021;11(2):91–106. https://doi.org/10.4236/ojst.2021.112008.
Mortazavi H, Safi Y, Baharvand M, Jafari S, Anbari F, Rahmani S. Oral white lesions: an updated clinical diagnostic decision tree. Dent J Basel. 2019;7(1):15. https://doi.org/10.3390/dj7010015.
Thomson P. Oral white lesions: who, what, where, when, how and why? Faculty Dental Journal. 2024Jan;15(1):30–6.
Aydemir B, Baykal Selçuk L, Aksu Arıca D, Metintaş AO. Oral lichen planus and oral lichenoid reactions: a retrospective evaluation of patch test results with dental series. Mucosa. 2021;4(1):17–22. https://doi.org/10.33204/mucosa.901221.
Rotim Z, Bolanca Z, Rogulj AA, Andabak M, Boras VV, Vrdoljak DV. Oral lichen planus and oral lichenoid reaction–an update. Acta Clin Croat. 2015Dec 1;54(4):516–20.
Cinar G, Metin A. Carbamazepine-induced oral lichenoid reaction: a report of a rare case. Cureus. 2025;17(4):e81835. https://doi.org/10.7759/cureus.81835.
Carrard VC, van der Waal I. A clinical diagnosis of oral leukoplakia; a guide for dentists. Med Oral Patol Oral Cir Bucal. 2018;23(1):e59–64. https://doi.org/10.4317/medoral.22292.
Chouchi M, Kaabachi W, Tizaoui K, Daghfous R, Aidli SE, Hila L. The HLA-B*15:02 polymorphism and Tegretol®-induced serious cutaneous reactions in epilepsy: an updated systematic review and meta-analysis. Rev Neurol (Paris). 2018;174(5):278–91. https://doi.org/10.1016/j.neurol.2017.11.006.
Najafi MR, Najafi MA, Shayan-Moghadam R, Saadatpour Z, Ghadimi K. Comparison of the efficacy of Tegatard and Tegretol as a monotherapy in patients with focal seizure with or without secondary generalization. Am J Clin Exp Immunol. 2020;9(4):58–63.
Lee JE, Min KR, Kim SH, Kim AH, Kim ST. Analysis of adverse drug reactions with carbamazepine and oxcarbazepine at a tertiary care hospital. Yonsei Med J. 2020;61(10):875–9. https://doi.org/10.3349/ymj.2020.61.10.875.
Funding
Not applicable.
Author information
Authors and Affiliations
Contributions
ABA.: Conceptualization, Design, Data collection, Analysis, Literature research, Original Draft, Writing - Review & Editing, ŞE: Conceptualization, Design, Project administration, Supervision, Methodology, SEK: Conceptualization, Design, Project administration, Supervision, Methodology, İO: Writing - Review & Editing, Visualization, Investigation, MFÇ: Visualization, Investigation, Data Curation.
Corresponding author
Ethics declarations
Ethics Approval and Consent to Participate
This study was performed in line with the principles of the Declaration of Helsinki. All the clinical procedures were legally authorized and approved by the Oral and Dental Health Application and Research Center Directorate/Uşak University. Informed consent was obtained from the patient in this study.
Consent for Publication
Written Consent for publication was obtained from the patient in this study.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Abed, A.B., Erensoy, Ş., Korcan, S.E. et al. Bilateral Symmetrical Oral Lichenoid Reaction in an Epileptic Patient due to Karbalex Retard (Carbamazepine) 600 mg: An Unusual Case Report. SN Compr. Clin. Med. 7, 316 (2025). https://doi.org/10.1007/s42399-025-02077-x
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s42399-025-02077-x